(4-propoxyphenyl)boronic acid

• ChemBase ID: 91510
• Molecular Formular: C9H13BO3
• Molecular Mass: 180.00872
• Monoisotopic Mass: 180.09577468
• SMILES: B(c1ccc(cc1)OCCC)(O)O
• Canonical SMILES: CCCOc1ccc(cc1)B(O)O
• InChI: InChI=1S/C9H13BO3/c1-2-7-13-9-5-3-8(4-6-9)10(11)12/h3-6,11-12H,2,7H2,1H3
• InChIKey: SOKFEJKZYHYKSY-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (4-propoxyphenyl)boronic acid
• IUPAC Traditional name: 4-propoxyphenylboronic acid
• Synonyms: 4-Propoxyphenylboronic acid; 4-Propoxybenzeneboronic acid; 4-PROPOXYPHENYLBORONIC ACID; 4-(3-Hydroxypropyl)benzeneboronic acid; 4-丙氧基苯基硼酸; 4-(3-羟基丙基)苯硼酸

Database IDs

• CAS Number: 186497-67-6; 850568-48-8
• MDL Number: MFCD04973734; MFCD03427189
• PubChem SID: 162078209; 24879690
• PubChem CID: 4456490

CALCULATED PROPERTIES

• Acid pKa: 8.87918
• H Acceptors: 3
• H Donor: 2
• LogD (pH = 5.5): 2.1980197
• LogD (pH = 7.4): 2.184102
• Log P: 2.1982
• Molar Refractivity: 46.3393 cm^3
• Polarizability: 19.73129 Å^3
• Polar Surface Area: 49.69 Å^2
• Rotatable Bonds: 4
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Melting Point: 123-126 °C(lit.); 70-74°C

Safety Information

• Storage Warning: Irritant
• European Hazard Symbols: Irritant (Xi)
• German water hazard class: 3
• Risk Statements: 36/37/38
• Safety Statements: 26-37-60
• TSCA Listed: 否
• GHS Pictograms: GHS07
• GHS Hazard statements: H315-H319-H335
• GHS Precautionary statements: P261-P305+P351+P338-P302+P352-P321-P405-P501A
• Personal Protective Equipment: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter

Product Information

• Purity: 96%; 98%
• Linear Formula: C6H4(OCH2CH2CH3)B(OH)2

DETAILS

Sigma Aldrich - 557706

Other Notes
Contains varying amounts of anhydride.
Packaging
5 g in glass bottle
Application
Reactant for:
• Synthesis of obovatol derivatives as anti-platelet activity1
• Suzuki-Miyaura reaction with chloro arenes using (phenylphosphine)palladium catalyst2
• Preparation of bisaryl substituted thiazoles and oxazoles as selective peroxisome proliferator-activated receptor δ (PPARδ) agonists3
• Selective BACE1 inhibitors using regioselective Suzuki coupling4
• Preparation of dichroic fluorescent benzothiadiazole dyes5